| Page 4 | Kisaco Research
 

Stephanie Vakaljan

Director of Trial Analytics and Decision Support
GSK

Stephanie Vakaljan

Director of Trial Analytics and Decision Support
GSK

Stephanie Vakaljan

Director of Trial Analytics and Decision Support
GSK
 

Michaela Tolman

Commercial Development Lead for Inflammation & Immunology
Pfizer

Michaela Tolman

Commercial Development Lead for Inflammation & Immunology
Pfizer

Michaela Tolman

Commercial Development Lead for Inflammation & Immunology
Pfizer
 

Michaela Tolman

Commercial Development Lead for Inflammation & Immunology
Pfizer

Michaela Tolman

Commercial Development Lead for Inflammation & Immunology
Pfizer

Michaela Tolman

Commercial Development Lead for Inflammation & Immunology
Pfizer

As cross-border patent disputes expand, companies now face parallel proceedings in the UK, the UPC, the US, and Asia. From Unwired Planet v. Huawei to Panasonic v. OPPO, courts are asserting global influence over licensing, validity, and enforcement. This session explores how strategic forum selection and procedural divergence are reshaping litigation outcomes and global IP strategy.

• Compare how the UK, UPC, US, and German courts approach jurisdiction, declaratory relief, and parallel enforcement.
• Examine how anti-suit injunctions, interim measures, and case sequencing are used to influence settlement leverage.
• Review recent cross-border disputes, including Edwards Lifesciences v. Meril Life Sciences and Apple v. Masimo, to identify emerging litigation patterns across sectors.

Author:

Tom Brown

Senior Managing Legal Director, Head of Intellectual Property Litigation
Dell

Tom Brown

Senior Managing Legal Director, Head of Intellectual Property Litigation
Dell
 

Laura Shaughnessy

Development Strategy Lead
UCB

Laura Shaughnessy

Development Strategy Lead
UCB

Laura Shaughnessy

Development Strategy Lead
UCB